Effectiveness of Changing the Class of Molecularly Targeted Agent after Disease Progression during Initial Molecularly Targeted Therapy for Luminal Advanced/Metastatic Breast Cancer
Abstract:Background:The emergence of molecular-targeted agents (MTAs) has altered the treatment landscape of hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC)/metastatic breast cancer (MBC). Various guidelines recommend molecular-targeted therapy as first-line treatment for HR+/HER2− ABC/MBC. However, subsequent treatment following progressive disease after MTA therapy remains undetermined. This study evaluated the suitability of different types of MTAs for s… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.